Key Points
- Director Luke Evnin sold 95,412 shares on April 28 for a total of $69,650.76 (at $0.73/share) and also sold shares on April 27 and 29; the trades were executed under a pre-arranged Rule 10b5-1 plan and reduced his position by 4.53% to 2,010,508 shares (≈$1.47M).
- Shares opened at $0.68 and were down 8.1%, with a 52-week range of $0.53–$2.38 and a market cap of ~$33.05M; analysts have a consensus rating of "Hold" with an average target price of $3.75.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 56,559 shares of the firm's stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $0.69, for a total transaction of $39,025.71. Following the completion of the sale, the director directly owned 1,953,949 shares of the company's stock, valued at approximately $1,348,224.81. The trade was a 2.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total transaction of $69,650.76.
- On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.85, for a total transaction of $45,849.00.
Werewolf Therapeutics Trading Down 8.1%
NASDAQ HOWL opened at $0.68 on Thursday. The firm's fifty day simple moving average is $0.81 and its two-hundred day simple moving average is $0.89. Werewolf Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $2.38. The firm has a market capitalization of $33.05 million, a P/E ratio of -0.50 and a beta of 0.54.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.14. As a group, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
HOWL has been the topic of several analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen raised shares of Werewolf Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, April 7th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $3.75.
View Our Latest Analysis on HOWL
Institutional Investors Weigh In On Werewolf Therapeutics
A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its holdings in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock valued at $2,774,000 after buying an additional 109,796 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company's stock valued at $429,000 after buying an additional 221,766 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics during the second quarter valued at $409,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Werewolf Therapeutics during the third quarter valued at $304,000. 64.84% of the stock is owned by hedge funds and other institutional investors.
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
